INDGN578.00

Indegene Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹13,901 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations2,589.62,839.33,510.53,812.8
Other Income76.3107.272.078.9
Total Income2,665.92,946.53,582.53,891.7
Expenses
+ Employee Benefit Expense1,651.61,815.22,197.72,375.3
+ Finance Costs49.422.019.322.0
+ Depreciation & Amortisation76.180.2126.4148.9
+ Other Expenses432.6489.8693.8799.6
Total Expenses2,209.72,407.23,037.23,345.8
EBITDA505.4534.3619.0637.9
EBIT429.3454.1492.6489.0
Profit
PBT before Exceptional Items456.2539.3545.3545.9
+ Exceptional Items2.40.0-20.3-20.3
Pretax Income458.6539.3525.0525.6
+ Current Tax125.5149.1176.3177.2
+ Deferred Tax-3.6-16.5-52.4-52.5
Tax Expense121.9132.6123.9124.7
Net Income336.7406.7401.1400.9
+ Net Income — Continuing Ops336.7406.7401.1400.9
+ Other Comprehensive Income7.925.6139.4134.5
Total Comprehensive Income344.6432.3540.5535.4
Net Income to Common344.6406.7401.1298.8
Per Share
Basic EPS15.1917.1516.7216.71
Diluted EPS15.0717.0216.6216.60
Other Comprehensive Income — detail
+ Other Comprehensive Income25.6139.4134.5
+ Items NOT to be Reclassified to P&L0.0-2.14.10.0
+ Tax on Items NOT to be Reclassified-0.51.00.0
+ Items to be Reclassified to P&L7.927.2134.6134.3
+ Tax on Items to be Reclassified0.0-1.7-0.2
Comprehensive Income — Owners of Parent7.9432.3139.4291.1
Per Share — as-filed variants
Basic EPS — Continuing Operations15.1917.1516.7216.71
Diluted EPS — Continuing Operations15.0717.0216.6216.60
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit2,589.62,839.33,510.53,812.8
Gross Margin %100.00100.00100.00100.00
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)456.2539.3545.3545.9
− Exceptional Items (reconciliation)2.40.0-20.3-20.3
Net Income Adj (tax-effected)334.9406.7416.6416.4
EPS Adj15.1117.1517.3717.36
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital44.447.948.148.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.